Clinical trials: Molecular Residual Disease
Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease.
- Conditions
- Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
- Trial name
- NCT06529822
- Testing
- Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Washington University School of Medicine
Molecular Residual Disease, Cancer
Unified Network for Integrated Fluid Collection at Yale
UNIFY is a Yale-wide liquid biopsy master repository that prospectively collects Streck-tube blood, dried blood spots (and optional archival tissue) from Yale Cancer Center patients across all tumor types for current and future…
- Trial name
- UNIFY (NCT07689864)
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Yale University
Non Small Cell Lung Cancer
Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer
This observational study will evaluate whether a blood test can detect the return of non-small cell lung cancer at least three months before it is identified on routine imaging.
- Trial name
- NCT07854769
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
This phase II trial tests reduced post surgery (adjuvant) therapy for patients with early breast cancer who have confirmed that the disease has responded completely (pathologic complete response) after pre surgical treatment…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma, Early Stage Triple-Negative Breast Carcinoma
- Trial name
- NCT07407920
- Testing
- Biospecimen Collection, Hormone Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Head and Neck Squamous Cell Carcinoma
Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma
This research study will include patients with high risk locally advanced head and neck squamous cell carcinoma (LA-HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx and patients that are starting on standard…
- Conditions
- Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT04599309
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer
Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel
This is a multicenter, prospective, observational study to evaluate the utility of the Invitae Personalized Cancer MonitoringTM assay for patients with resectable and unresectable pancreatic cancer.
- Trial name
- ARTEMIS-PC (NCT06043921)
- Testing
- No intervention
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Invitae Corporation
Glioma
Tessa Jowell BRAIN MATRIX - Platform Study
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis.
- Trial name
- BRAIN MATRIX (NCT04274283)
- Testing
- Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
- Where
- 14 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Birmingham
Sensorineural Hearing Loss
Immunity After Cochlear Implantation and Perilymph Molecular Profiles in Sensorineural Hearing Loss
Many patients receiving cochlear implant (CI) have some residual hearing prior to implantation surgery. However, approximately one third of them will lose it in next 6 months after cochlear implantation.
- Trial name
- PERILOTO (NCT05670158)
- Testing
- Blood sampling, Perilymph sampling
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Montpellier
Leukemia, Myeloid, Chronic-Phase
Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response
The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response and major molecular response rate) is…
- Trial name
- MIM (NCT01827930)
- Testing
- Imatinib Mesylate 600 MG Oral Tablet, Imatinib Mesylate 400 MG Oral Tablet, Imatinib Mesylate
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Institut Bergonié
CML (Chronic Myelogenous Leukemia
IIT PH1 KDS-1001 in Patients With CML
This open label, non-randomized, prospective phase I study is designed to evaluate if the addition of natural killer cell therapy (KDS-1001) to tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) patients with…
- Trial name
- NCT04808115
- Testing
- KDS-1001
- Sponsor
- Duke University
Chronic Myeloid Leukemia
Nilotinib Plus Pegylated Interferon-α2b in CML
The purpose of this trial is to assess the effect of switching CML patients, who have been treated with imatinib ≥ 2 years and who have stable detectable molecular residual disease between 0.01-1.0% (IS), to the combination of…
- Trial name
- NCT01866553
- Testing
- Nilotinib, Pegylated interferon α-2b
- Where
- 5 sites in Denmark, Finland and 3 more
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
ER-positive, HER2-negative Breast Cancer, Breast Cancer Stage I
Capecitabine in ER+/HER2-negative Breast Cancer
This is a Phase 2 study for patients with resected Stage I-III HR+/HER2-negative breast cancer with detected molecular residual disease (MRD+) following standard neo/adjuvant and locoregional therapy delivered with curative…
- Conditions
- ER-positive, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT07631052
- Testing
- Capecitabine
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Muscle-Invasive Bladder Carcinoma
Clinical Performance Evaluation of the C2i-Test
The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing…
- Trial name
- NCT05221827
- Testing
- C2i Test
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- C2i Genomics
Coronary Arterial Disease (CAD)
Health Improvements by Understanding the Determinants of Residual Risk in Coronary Artery Disease and New Targets for Prevention and Treatment
Current medical treatments, in patients with stable coronary artery disease (CAD), mainly target established risk factors and are able to reduce morbidity and mortality but still leave a substantial residual risk of coronary…
- Trial name
- HURRICANE (NCT06601153)
- Testing
- Cardiac CT
- Where
- 2 sites in Italy
- Volunteers
- 961 people
- Sponsor
- Fondazione Toscana Gabriele Monasterio
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
The purpose of this study is to evaluate the efficacy of tyrosine kinase inhibitor(TKI) therapy based on molecular monitoring of BCR/ABL levels in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)undergoing…
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation, Minimal Residual Disease
- Trial name
- NCT01883219
- Testing
- TKIs
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Colorectal Cancer, Colon Cancer
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving therapy with regorafenib and XmAb20717 (also known as vudalimab).
- Conditions
- Colorectal Cancer, Colon Cancer, Rectum Cancer
- Trial name
- NCT05900648
- Testing
- Regorafenib, XmAb20717
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Lung Cancer
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD).
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Gynecologic Cancer
- Trial name
- SHERLOCK (NCT07524114)
- Where
- Canada
- Volunteers
- 7,000 people
- Sponsor
- University Health Network, Toronto
Breast Cancer, Melanoma
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular…
- Conditions
- Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
- Trial name
- NIP IT! (NCT05196087)
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer, Resectable Carcinoma
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer.
- Trial name
- MAP-02 (NCT05802407)
- Testing
- Later-line therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer, Residual Disease
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional…
- Conditions
- Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC), Stage II/III
- Trial name
- PREDICT-RD (NCT07069595)
- Testing
- Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center